S&P 500   3,848.05 (+0.17%)
DOW   30,887.84 (-0.35%)
QQQ   327.49 (+0.64%)
AAPL   142.66 (+2.58%)
MSFT   229.09 (+1.39%)
FB   277.15 (+0.97%)
GOOGL   1,875.59 (-0.90%)
AMZN   3,300.64 (+0.26%)
TSLA   870.36 (+2.80%)
NVDA   544.78 (-0.68%)
BABA   260.62 (+0.77%)
CGC   32.62 (-3.49%)
GE   10.95 (-1.44%)
MU   81.41 (-1.06%)
AMD   93.82 (+1.11%)
NIO   59.87 (-3.36%)
T   29.11 (+0.62%)
F   11.07 (-3.91%)
ACB   10.06 (-5.54%)
BA   202.26 (-1.74%)
DIS   170.82 (-1.13%)
NFLX   554.46 (-1.90%)
GILD   67.58 (+0.96%)
S&P 500   3,848.05 (+0.17%)
DOW   30,887.84 (-0.35%)
QQQ   327.49 (+0.64%)
AAPL   142.66 (+2.58%)
MSFT   229.09 (+1.39%)
FB   277.15 (+0.97%)
GOOGL   1,875.59 (-0.90%)
AMZN   3,300.64 (+0.26%)
TSLA   870.36 (+2.80%)
NVDA   544.78 (-0.68%)
BABA   260.62 (+0.77%)
CGC   32.62 (-3.49%)
GE   10.95 (-1.44%)
MU   81.41 (-1.06%)
AMD   93.82 (+1.11%)
NIO   59.87 (-3.36%)
T   29.11 (+0.62%)
F   11.07 (-3.91%)
ACB   10.06 (-5.54%)
BA   202.26 (-1.74%)
DIS   170.82 (-1.13%)
NFLX   554.46 (-1.90%)
GILD   67.58 (+0.96%)
S&P 500   3,848.05 (+0.17%)
DOW   30,887.84 (-0.35%)
QQQ   327.49 (+0.64%)
AAPL   142.66 (+2.58%)
MSFT   229.09 (+1.39%)
FB   277.15 (+0.97%)
GOOGL   1,875.59 (-0.90%)
AMZN   3,300.64 (+0.26%)
TSLA   870.36 (+2.80%)
NVDA   544.78 (-0.68%)
BABA   260.62 (+0.77%)
CGC   32.62 (-3.49%)
GE   10.95 (-1.44%)
MU   81.41 (-1.06%)
AMD   93.82 (+1.11%)
NIO   59.87 (-3.36%)
T   29.11 (+0.62%)
F   11.07 (-3.91%)
ACB   10.06 (-5.54%)
BA   202.26 (-1.74%)
DIS   170.82 (-1.13%)
NFLX   554.46 (-1.90%)
GILD   67.58 (+0.96%)
S&P 500   3,848.05 (+0.17%)
DOW   30,887.84 (-0.35%)
QQQ   327.49 (+0.64%)
AAPL   142.66 (+2.58%)
MSFT   229.09 (+1.39%)
FB   277.15 (+0.97%)
GOOGL   1,875.59 (-0.90%)
AMZN   3,300.64 (+0.26%)
TSLA   870.36 (+2.80%)
NVDA   544.78 (-0.68%)
BABA   260.62 (+0.77%)
CGC   32.62 (-3.49%)
GE   10.95 (-1.44%)
MU   81.41 (-1.06%)
AMD   93.82 (+1.11%)
NIO   59.87 (-3.36%)
T   29.11 (+0.62%)
F   11.07 (-3.91%)
ACB   10.06 (-5.54%)
BA   202.26 (-1.74%)
DIS   170.82 (-1.13%)
NFLX   554.46 (-1.90%)
GILD   67.58 (+0.96%)
Log in
NASDAQ:CCXI

ChemoCentryx Stock Forecast, Price & News

$64.47
+0.07 (+0.11 %)
(As of 01/25/2021 02:33 PM ET)
Add
Compare
Today's Range
$64.15
Now: $64.47
$67.13
50-Day Range
$57.31
MA: $60.89
$65.16
52-Week Range
$30.72
Now: $64.47
$65.43
Volume24,021 shs
Average Volume514,136 shs
Market Capitalization$4.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
ChemoCentryx logo

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

336th out of 1,923 stocks

Pharmaceutical Preparations Industry

176th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900
Employees82
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.13 million
Book Value$1.14 per share

Profitability

Net Income$-55,490,000.00

Miscellaneous

Market Cap$4.46 billion
Next Earnings Date3/9/2021 (Estimated)
OptionableOptionable
$64.47
+0.07 (+0.11 %)
(As of 01/25/2021 02:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

How has ChemoCentryx's stock price been impacted by Coronavirus (COVID-19)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has increased by 56.4% and is now trading at $64.97.
View which stocks have been most impacted by COVID-19
.

Is ChemoCentryx a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ChemoCentryx?

Wall Street analysts have given ChemoCentryx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for ChemoCentryx
.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) released its quarterly earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.04. The biopharmaceutical company had revenue of $5.09 million for the quarter, compared to analysts' expectations of $12.86 million. ChemoCentryx had a negative net margin of 58.10% and a negative trailing twelve-month return on equity of 17.23%.
View ChemoCentryx's earnings history
.

What price target have analysts set for CCXI?

8 Wall Street analysts have issued 1-year target prices for ChemoCentryx's stock. Their forecasts range from $58.00 to $119.00. On average, they expect ChemoCentryx's share price to reach $77.13 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price.
View analysts' price targets for ChemoCentryx
or view Wall Street analyst' top-rated stocks.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 61, Pay $968.76k)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 57, Pay $696.65k)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 59, Pay $563.8k)
  • Ms. Kari E. Leetch, Sr. VP of HR
  • Dr. Catherine Lee Kelleher, Sr. VP of Clinical Devel.
  • Ms. Dalia R. Rayes, Sr. VP & Head of Commercial
  • Dr. Sangita Ghosh Ph.D., Sr. VP of Technical Operations

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.30%), Genesee Capital Advisors LLC (0.04%), Strs Ohio (0.02%) and Pacer Advisors Inc. (0.00%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Rajinder Singh, Susan M Kanaya, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx
.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx
or view top insider-selling stocks.

Which major investors are buying ChemoCentryx stock?

CCXI stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Pacer Advisors Inc., and Genesee Capital Advisors LLC.
View insider buying and selling activity for ChemoCentryx
or or view top insider-buying stocks.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $64.97.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $4.50 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.